Category Archives: Stem Cell Clinic


Updated: FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial – Endpoints News

Four months after a patient death forced Cellectis to halt one of their off-the-shelf CAR-T trials, the FDA has given them the OK to start dosing patients again.

The Paris-based biotech said they changed the studys protocol to accommodate the agencys concerns, although they will still have to work with investigators to obtain local approval to restart the trial and start recruiting patients again. Prior its halt, the Phase I had sites in New York, New Jersey and Texas.

Cellectis did not disclose what the changes were, but after the initial hold, analysts suggested the company might monitor patient cytokine levels more closely, swap out of one of the chemotherapy drugs used or prevent patients who have previously received an experimental multiple myeloma CAR-T from enrolling.

The companys stock {CLLS} rose 5.6% on the news, from $19.70 to $20.80.

Though partnered with the new upstarts such as Arie Belldegruns Allogene, Cellectis, a 21-year-old company, has been working on off-the-shelf versions to the first CAR-Ts since before those CAR-Ts were approved.

One of three different solo projects now in the clinic, the halted study, MELANI-01, is testing a cell therapy for multiple myeloma. If effective, it could serve as a potentially easier way to manufacture and administer an alternative to the multiple myeloma CAR-Ts now nearing approval from J&J and Legend Biotech and from bluebird bio and Bristol Myers Squibb.

When they announced the hold, Cellectis CMO Carrie Brownstein said that the company had already independently decided to move forward with dose level 1 in the study. The patient who died had been the first to receive dose level 2, an infusion of 3 million cells per kilogram. They developed cytokine release syndrome, the hallmark side effect of CAR-T therapy, and died of cardiac arrest 25 days later.

The dose 1 level involves 1 million cells per kilogram.

The FDA has been on high alert for safety issues in cell therapy trials, and this wasnt the first time theyve paused a Cellectis study. Back in 2017, another patient death paused development of UCART123.

After some protocol adjustments, the therapy was allowed to go back into patients. It is now in a Phase I for acute myeloid leukemia.

More:
Updated: FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial - Endpoints News

FUJIFILM Cellular Dynamics and Lonza Agree to Expand the Availability and Use of Induced Pluripotent Stem Cell Technology – BioSpace

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.

We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more atwww.lonza.comand follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.

About FUJIFILM

FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) utilized in drug discovery and cell therapies. FCDI is using its expertise in iPSC technologies to develop a robust cell therapeutics pipeline to address unmet medical needs in areas such as age-related macular degeneration, retinitis pigmentosa and immuno-oncology. For its partners, FCDI utilizes its iPSC platform to advance the progress of therapeutic candidates in the clinic and provides contract development and manufacturing (CDMO) services. In addition to cell therapy, FCDI also offers life science research tools including the companys inventoried iCell products, which are available in almost any cell type and are sourced from multiple cell lines which can be applied for target identification as well as toxicity testing. The company also offers custom cell development services and cell banking. FCDIs goal is to leverage the vast utility of iPSCs to advance human health and improve the quality of life for patients around the world. For more information, please visit:https://fujifilmcdi.com

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit:www.fujifilmholdings.com

Lonza Contact Details

FUJIFILM Contact Details:

Christine Jackman

FUJIFILM

(914) 789-8523

christine.jackman@fujfilm.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (SGX-ST). Lonza Group Ltd is not subject to the SGX-STs continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this newsrelease. All product and company names herein may be trademarks of their registered owners.

See the article here:
FUJIFILM Cellular Dynamics and Lonza Agree to Expand the Availability and Use of Induced Pluripotent Stem Cell Technology - BioSpace

Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin – FierceBiotech

The idea of repurposingexisting medicines as a fast approach to containing COVID-19 is still popular, even as vaccines and antibodies designed to combat the disease are starting to gain steam. Scientists at the Cleveland Clinic are among those examining existing compounds as possible treatments for the coronavirus, and now they're suggesting that the popular over-the-counter sleep aid melatonin may be a possible option in treating the disease.

The researchers used an artificial intelligence tool to analyze data from 26,779 individuals in the Cleveland Clinics COVID-19 registry, of whom 8,274 tested positive for SARS-CoV-2, the novel coronavirus that causes COVID-19.

They found that people who were taking melatonin were 28% less likely to test positive for SARS-CoV-2, after adjusting for factors such as age, sex and underlying diseases, according to results published in the journal PLOS Biology.

Much has been written about the promise of real-world data (RWD) in life sciences, but how does it work in practice? We address this question in a new whitepaper that demonstrates the potential benefits of new RWD technologies with a proof of concept study to show how RWD can be incorporated into clinical research.

The melatonin effect was more pronounced in African Americans, with a reduction of 52%. In White Americans, the number was 23%.

Melatonin is a hormone released by the body that regulates the sleep-wake cycle. As a dietary supplement, its commonly used to help manage insomnia andjet lag.

Besides melatonin, the Cleveland Clinic team also found that the beta-blocker carvedilol, sold under the brand Coreg for high blood pressure and other heart diseases, was associated with a 26% reduction in a persons chance of testing positive for SARS-CoV-2.

RELATED:Melatonin? Stem cells? Researchers step up with unconventional approaches to COVID-19

Some members of the same Cleveland Clinic team previously pinpointed melatonin among a group of drugs they suggested might work for COVID. They showed that melatonin and mercaptopurine might work as a good combo for COVID. Those findings came from a pharmacology-based platform that used a technique called network proximity analysis. It was based on the idea that some proteins involved in other diseases might hold proximity to a virus interaction with the host.

The researchersapplied the same method in the current study to shed a light on clinical manifestations and pathologies common between COVID-19 and 64 other diseases. Closer proximity would mean a higher likelihood of pathological associations between the diseases.

They found that proteins involved in respiratory distress syndrome and sepsis were highly connected with SARS-CoV-2. That wasnt a surprise given that the two disorders can also cause death in patients with severe COVID-19.

This signals to us that a drug already approved to treat these respiratory conditions may have some utility in also treating COVID-19 by acting on those shared biological targets, Feixiong Cheng, Ph.D., the studys senior author, said in a statement.

Overall, they identified close network proximity to SARS-CoV-2 proteins from inflammatory bowel disease, attention deficit hyperactivity disorder, as well as pulmonary diseases such as COPD. Using a computational model, they identified 34 drugs that were significantly proximal to two or more SARS-CoV-2 host protein sets.

RELATED:COVID-19: Bio researchers race to repurpose everything from antiviral to anticancer discoveries

A team at Columbia University has also linked melatonin with increased likelihood of clinical improvement among critically ill COVID-19 patients on intubation or mechanical ventilation.

The sleep-promoting supplement was also reportedly used by President Donald Trump during his COVID-19 infection, though its not clear if he was taking it specifically to treat the disease or as part of his daily nutrition routine.

Despite melatonin emerging as a top pick from the Cleveland Clinic registry, Cheng cautioned that larger, randomized control trials would be needed before the supplement could be widely adopted in the treatment of COVID-19.

Cheng added that AI-based approaches to analyzing COVID-19 patient registries should be embraced in the effort to find effective treatments for the disease.Recent studies suggest that COVID-19 is a systematic disease impacting multiple cell types, tissues and organs, so knowledge of the complex interplays between the virus and other diseases is key to understanding COVID-19-related complications and identifying repurposable drugs, Cheng said. Our study provides a powerful, integrative network medicine strategy to predict disease manifestations associated with COVID-19 and facilitate the search for an effective treatment.

Read the rest here:
Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech

Global Cancer Stem Cell Therapy Market Outlook by Types, Applications, End Users and Opportunities to 2025 – TechnoWeekly

The Cancer Stem Cell Therapy market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. The report provides key statistics on the market status of the Cancer Stem Cell Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Complete report on Cancer Stem Cell Therapy market spread across 83 pages, profiling companies and supported with tables and figures is now available @ https://www.insidemarketreports.com/sample-request/4/559333/Cancer-Stem-Cell-Therapy

We encourage businesses to become economically viable, socially acceptable, ethical & yet revolutionary research in technology as well as its profitable marketing with a greater conscience.

The global Cancer Stem Cell Therapy market 2020 research is a professional and in-depth study on the current state of the industry and provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Cancer Stem Cell Therapy market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

This report presents the worldwide Cancer Stem Cell Therapy market size (value, production and consumption), splits the breakdown (data status 2015-2019 and forecast to 2025), by manufacturers, region, type and application. This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

Companies profiled and studied for this Cancer Stem Cell Therapy market report include AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems and others.

The Report is segmented by types Autologous Stem Cell Transplants, Allogeneic Stem Cell Transplants, Syngeneic Stem Cell Transplants, Others and by the applications Hospital, Clinic, Medical Research Institution, Others,.

The report focuses on global major leading industry players of Cancer Stem Cell Therapy market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Cancer Stem Cell Therapy market development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

With tables and figures helping analyze worldwide Cancer Stem Cell Therapy market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Purchase the copy of this report at: https://www.insidemarketreports.com/buy-now/4/559333/Cancer-Stem-Cell-Therapy/single

Purchase this Report now by availing up to 40% Discount and free consultation. Limited offer only.

Why Inside Market Reports:

For all your Research needs, reach out to us at:

Email: [emailprotected]

Phone:+1-617-230-0741

Continue reading here:
Global Cancer Stem Cell Therapy Market Outlook by Types, Applications, End Users and Opportunities to 2025 - TechnoWeekly

Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease – PRNewswire

KING OF PRUSSIA, Pa., Nov. 2, 2020 /PRNewswire/ --Global biotherapeutics leader CSL Behring announced today that its investigational, plasma-derived hemopexin therapy (CSL889) received orphan drug designation from both the European Commission and the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for the treatment of sickle cell disease (SCD). These designations grant special status to drugs and biological products intended to treat a rare disease, affecting less than 200,000 patients in the US or affecting not more than five in 10,000 people in the European Union.

CSL889 is a form of plasma-derived hemopexin, an important, naturally occurring protein produced in the body whose levels are decreased in patients with SCD. Low levels of hemopexin have been associated with increased symptoms in SCD, particularly acute vaso-occlusive crises (VOC). VOC, the most common manifestation in SCD, are severe, debilitating episodes characterized by severe pain. There is no approved treatment for acute VOC, so episodes can only be managed with supportive measures such as fluids and pain killers.

"Having treated hundreds of adults and children living with sickle cell disease over 30 years, I'm intensely aware of the need for novel and effective therapies, especially to relieve the tremendous pain from VOC," said Professor Greg Kato, who is leading the clinical development of CSL 889 at CSL Behring. "This newly granted orphan status recognizes the urgency for progressing new treatment options into the clinic."

CSL Behring has two Phase I SCD programs poised to evolve the treatment paradigm for patients: CSL889 hemopexin therapy for the treatment of VOC and CSL200 lentiviral stem cell gene therapy for long-term disease management.

About Sickle Cell Disease

Sickle Cell Disease is a hereditary blood disorder in which red blood cells contain an abnormal type of hemoglobin, causing some of the cells to become distorted into a crescent, or sickle-shape. These misshapen red blood cells have difficulty passing through small blood vessels, slowing and blocking blood flow to areas of the body, damaging tissue that isn't receiving a normal flow of blood. Sickle Cell Disease can lead to episodes of severe pain, strokes, kidney, lung and heart problems, slow growth, vision problems and infection vulnerability. While frequency of Sickle Cell Disease varies globally, it is estimated to impact 100,000 people in the US and 1 in 10,000 persons in the European Union.

About CSL Behring

CSL Behringis a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 27,000 people, anddelivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring.

SOURCE CSL Behring

Original post:
Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease - PRNewswire

What’s On The Ballot? Here’s A Look At California’s 2020 Propositions – KPBS

Listen to the Podcast Episode

While much of the attention on the November election is focused on the race for President, Californians are going to have a lot of other decisions to make. One (or 12) of the biggest: the statewide ballot measures.

Aired: November 2, 2020 | Transcript

While much of the attention on the November election is focused on the race for President, Californians are going to have a lot of other decisions to make. One (or 12) of the biggest: the statewide ballot measures.

Yes, there will be a dozen different propositions for California voters this year Prop. 14 through Prop. 25 on everything from expanding rent control to ending the ban on affirmative action. While we at CapRadio will be reporting on these more up until Nov. 3, we wanted to give you a quick overview now on what each measure covers and what a "yes" or "no" vote will mean.

Here are the basics of what you need to know about each proposition (including videos from our colleagues at CalMatters and more reporting from CapRadio):

Proposition 14: Stem cell research

A yes vote on this measure would authorize the state to purchase these bonds, increasing funding for stem cell research on treatments for cancer, Alzheimers and dozens of other diseases.

A no vote would prevent the state from issuing these bonds.

Learn More About Prop. 14

Proposition 15: 'Split roll'

Known as the "split roll" measure, Proposition 15 would increase taxes on factories, stores and other commercial and industrial real estate worth $3 million or more. It would do this by requiring owners pay property tax based on market value, rather than what is often a much lower tax rate based on the original purchase price.

The measure is considered one of the largest revisions of Proposition 13, the landmark 1978 initiative that slashed property taxes and limited how much they could go up. Residential and agricultural properties would be exempt from the changes. The split roll measure would raise an estimated $6.5 billion to $11.5 billion annually, according to an analysis by the nonpartisan Legislative Analysts Office. The money would be distributed to K-12 public schools, community colleges and local governments.

A yes vote on this measure would revise Proposition 13, increasing taxes on factories, stores and other commercial and industrial real estate by requiring owners to pay property tax based on its market value, rather than based on what they bought the property for.

A no vote on this measure would allow owners of these properties to continue to pay what is often a much lower tax rate based on the original purchase price.

Learn More About Prop. 15

Proposition 16: End ban on affirmative action

If passed by voters, this state constitutional amendment would end Californias ban on affirmative action. It would allow schools and public agencies to take race, ethnicity and sex into account when making admission, hiring or contracting decisions. It would repeal portions of Proposition 209, the constitutional amendment California voters passed in 1996 prohibiting affirmative action at state institutions.

A yes vote on this measure would allow government agencies to set goals for recruiting diverse employees and granting contracts to women and minority-owned businesses. These considerations are meant to give a leg up to historically disadvantaged communities.

A no vote would continue the ban on these affirmative action practices created by Proposition 209.

Learn More About Prop. 16

Proposition 17: Voting rights for previously incarcerated people

This constitutional amendment would allow people on parole for felony convictions to vote after their state or federal prison term ends. The states constitution prohibits people with felony convictions from voting until both their incarceration and parole are finished. The change, proposed by state lawmakers, would affect approximately 40,000 Californians, according to a state Senate analysis.

A yes vote on this proposition would allow people on parole for felony convictions to vote.

A no vote on this proposition would continue to prohibit people with felony convictions from voting until both their prison term and their parole are over.

Proposition 18: 17-year-olds voting in primaries

If passed, this constitutional amendment would expand voting rights for certain 17-year-olds in California. Citizens who are 17, residents of the state and will be at least 18 years old at the time of the next general election, would be allowed to vote in any primary or special election that occurs before the next general election. State lawmakers placed this measure on the November ballot.

A yes vote on this proposition would allow these qualifying 17-year-olds to vote in primaries or special elections if they will be 18 by the general election.

A no vote on this would not expand voting rights to these 17-year-olds.

Proposition 19: Transfer of property tax breaks

This would allow homeowners who are over 55, disabled or victims of natural disasters to transfer part of their property tax base with them when they sell their home and purchase a new one. The constitutional amendment would also prevent people who inherit family properties from keeping the low property tax base unless they use the home as their primary residence and the market value is less than $1 million. Most of the revenue from the measure would fund wildfire agencies.

A yes vote on this measure would allow these homeowners who are seniors, disabled or have been victims of a natural disaster to keep a lower property tax rate when they buy a new home.

A no vote on this measure would not allow these qualifying homeowners to keep their lower property tax base when they sell their home and purchase a new one.

Proposition 20: Criminal sentencing

This measure would roll back some changes to Californias criminal sentencing laws approved over the past decade. It would authorize judges to impose felony charges on certain theft or fraud crimes currently chargeable only as misdemeanors. It would also restrict the number of inmates eligible for parole by adding drug, theft and other crimes to the list of violent crimes or sentence enhancements excluded from parole review. Lastly, the measure would require people convicted of drug, theft or domestic violence misdemeanors to submit to DNA collection for the state database.

A yes vote on this measure would allow judges to charge more crimes as felonies, restrict the number of inmates eligible for parole and increase the number of people who will submit their DNA to the states criminal database.

A no vote on this measure would not enact the changes listed.

Learn More About Prop 20

Proposition 21: Rent control

Prop 21 would allow cities and counties to implement rent control for certain residential properties over 15 years old. The initiative's official summary says it would grant exemptions from new rent control policies for individuals who own no more than two homes. The measure is meant to replace the Costa-Hawkins Rental Housing Act, which prohibited rent control for housing that was built after 1995 as well as for units such as single-family homes, townhomes and condos.

A yes vote on this measure would allow cities and counties to put rent control policies into place on these properties.

A no vote on this measure would continue the provisions of Costa-Hawkins.

Learn More About Prop. 21

Proposition 22: Rules for app-based drivers

This would exempt certain gig workers from AB5, Californias contentious new labor law, by reclassifying app-based delivery and rideshare drivers as independent contractors. Funded by companies including Uber, Lyft and DoorDash, Prop 22 would require companies with independent contract drivers to provide their drivers with benefits like minimum compensation and health care subsidies based on driving time, vehicle insurance and sexual harassment training rather than regular employee benefits like a minimum wage, workers compensation or overtime pay.

A yes vote on this measure would allow companies not to classify drivers as regular employees, but would require them to provide them with the benefits listed above.

A no vote on this measure would continue AB5s requirement that these drivers be classified as employees and be provided minimum wage, workers compensation and overtime pay.

Learn More About Prop. 22

Proposition 23: Dialysis clinic rules

If approved, Proposition 23 would require dialysis clinics to have a licensed physician, nurse or physician assistant on site during kidney dialysis treatment. It would require outpatient clinics to report data on dialysis-related infections, ban them from discriminating against patients based on their source of payment or care, and require state approval to shut down a dialysis clinic.

A yes vote on this measure would add these new requirements on dialysis clinics.

A no vote on this measure would allow dialysis clinics to continue operating as they have been.

Proposition 24: Consumer privacy

Proposition 24 would allow Californians to block companies from sharing personal information and limit businesses use of sensitive personal information including geolocation, private communications, race or ethnicity, religion, union membership and health or biometric data. It raises maximum penalties for violations involving consumers under the age of 16. The measure would also create a new state agency to enforce consumer privacy regulations, which is estimated to cost about $10 million per year.

A yes vote on this measure would enact these new privacy protections and create a new state agency to enforce the regulations.

A no vote on this measure would not change California's data privacy law.

Its Election Day. It's the last day to cast your ballot in person, or to post mark your mail in ballot. KPBS will have coverage throughout today to bring you the election latest. Also, the tensions around Election Day have hospitals on high alert, even though those institutions are always planning ahead for disasters that could send a wave of ... Read more

Aired: November 3, 2020 | Transcript

Some people in San Diego and Tijuana can vote on both sides of the U.S.-Mexico border.

In a new episode of Port of Entry," we profile three of these binational citizens who can vote in elections in the U.S. and Mexico. And while you might think these folks all fall on the same side of the political fence when ... Read more

Aired: October 23, 2020 | Transcript

KPBS Midday Edition is a daily radio news magazine keeping San Diego in the know on everything from politics to the arts.

To view PDF documents, Download Acrobat Reader.

Read the original here:
What's On The Ballot? Here's A Look At California's 2020 Propositions - KPBS

The Animal Stem Cell Therapy market to witness remarkable disruptions in the next decade – TechnoWeekly

Animal stem cell therapy is a usage of animals stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or disease. The animal stem cell therapy process involve three steps which include collection of stem cell sample from animals and preparing the sample to concentrate the stem cells. Finally, the therapy includes transferring the stem cells into the injured site for treatment. Animal stem cell therapy increases the expectancy of life in animals with no side effects. It is available for the treatment of arthritis, degenerative joint disorders, tendon, and ligaments injuries in animals. Stem cell therapy is most often used to treat dogs, cats, and horses. But recent developments made it possible to use animal stem cell therapy in tiger, pig, etc. Present animal stem cell therapy is studied in treatments of the inflammatory bowel, kidney, liver, heart and immune-mediated diseases respectively.

Animal Stem Cell Therapy Market: Drivers and Restraints

Increasing prevalence of disease in animals with growing population and to increase the animals quality of life, the companies focus shifting towards animal stem cell therapies. Along with increasing government funding for the protection of animals and fast approvals of FDA contributing towards the rapid growth of the animal stem cell therapy. The research in animal stem cells offers great promise for understanding underlying mechanisms of animal development; it gives great opportunities to treat a broad range of diseases and conditions in animals. Animal stem cell therapy is increasingly recognized as critical translational models of human disease for treatment. All these factors act as drivers for the robust growth of the animal stem cell therapy market.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/14941

Animal Stem Cell Therapy Market: Segmentation

Segmentation based on Applications

Segmentation based on End-user

Animal Stem Cell Therapy Market: Market Overview

Studies in the animal stem cell therapy continue at a breathtaking pace due to increasing demand and treatment cost covered in reimbursements. And animal stem cell therapy is more effective than traditional treatment available in the market which is boosting the companies to increase the spending in the R&D for innovative methods. Because of the novelty and complexity of animal stem cell therapy, FDA encourages individuals, universities and drug companies for further innovations. The future expected with double CAGR during the forecasted period.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/14941

Animal Stem Cell Therapy Market: Region-wise Overview

Regarding geographies, North America is dominating the global animal stem cell therapy market due to the increased incidence rate and awareness about the therapy. U.S represents the largest market share in the North America due to the increasing demand for the therapy. Europe and Asia-Pacific are showing a significant growth rate during the forecasted period due to the growing adoption of the animal stem cell therapy. The animal stem cell therapy market in underdeveloped countries is slow when compared to the developed countries.

Animal Stem Cell Therapy Market: Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/14941

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved Beg Persistence Market Research Address 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Sales[emailprotected] Websitehttps://www.persistencemarketresearch.com

Follow this link:
The Animal Stem Cell Therapy market to witness remarkable disruptions in the next decade - TechnoWeekly

Dr. Hill on Next Steps for Research Exploring CAR T-Cell Therapy in MCL – OncLive

Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.

Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and staff physician at Taussig Cancer Institute, as well as an assistant professor of Hematology and Oncology at the Cleveland Clinic, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma (MCL).

Two questions regarding the use of CAR T-cell therapy in MCL involve moving the therapy up into earlier lines of treatment and using it in combination with other agents, says Hill. Thus far, there have been no compelling reasons to combine other therapies with CAR T-cell treatment for lymphoma,Hill explains. However, studies are looking into this concept, adds Hill.

In terms of using CAR T-cell therapy in earlier lines of treatment, many ongoing discussions are focused on examining the use this approach in certain populations with high-risk disease, according to Hill. These populations includethose with TP53 mutations or a blastoid variant of MCL, a subtype that has historically yielded particularly poor outcomes with traditional chemotherapy and high-dose chemotherapy, as is used in autologous stem cell transplant, concludes Hill.

Read more from the original source:
Dr. Hill on Next Steps for Research Exploring CAR T-Cell Therapy in MCL - OncLive

Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Inflamed Gut of Patients With Crohn’s Disease and Ulcerative Colitis -…

NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a randomized, controlled study of remestemcel-L delivered by an endoscope directly to the areas of inflammation and tissue injury in up to 48 patients with medically refractory Crohns disease and ulcerative colitis has commenced at Cleveland Clinic.

Mesoblast Chief Medical Officer Dr Fred Grossman said: Inflammation of the gut in Crohns disease and ulcerative colitis closely resembles the most severe manifestation of advanced-stage, life-threatening acute graft versus host disease (aGVHD). Mesoblasts objective is to confirm the potential for remestemcel-L to induce luminal healing and early remission in a wider spectrum of diseases with severe inflammation of the gut, in addition to steroid-refractory aGVHD.

Mesenchymal stem cells (MSCs) promote healing of inflamed gut tissue by downregulating gut mucosal effector T-cell activity and promoting regulatory T-cell formation.1 MSCs have been tested in clinical trials of Crohns disease using two different modalities: intravenous infusions of MSCs to treat the primary inflammation of Crohns disease and local injections of MSCs to treat fistulae complicating Crohns disease.

A third modality, endoscopic delivery of MSCs, has been successful in preclinical experimental models of colitis, reducing the excessive cytokine storm in the inflamed gut and resulting in tissue healing.2-3 The study at Cleveland Clinic will be the first in humans using local delivery of MSCs in the gut, and will enable Mesoblast to compare clinical outcomes using this delivery method with results from an ongoing randomized, placebo-controlled trial in patients with biologic-refractory Crohns disease where remestemcel-L was administered intravenously.

The studys lead investigator Dr Amy L. Lightner, Associate Professor of Surgery in the Department of Colon and Rectal Surgery at Cleveland Clinic, stated: We are aiming to establish a new treatment paradigm by administering remestemcel-L at one of two escalating doses, or placebo, directly to inflamed gut tissue in patients with medically refractory Crohns disease and ulcerative colitis, both highly debilitating conditions with significant, unmet medical needs.

According to recent estimates, more than three million people (1.3%) in the US alone have inflammatory bowel disease, with more than 33,000 new cases of Crohns disease and 38,000 new cases of ulcerative colitis diagnosed every year.4-6 Despite recent advances, approximately 30% of patients are primarily unresponsive to anti-TNF agents and even among responders, up to 10% will lose their response to the drug every year. Up to 80% of patients with medically-refractory Crohns disease eventually require surgical treatment of their disease,7 which can have a devastating impact on quality of life.

References 1.Mayne C and Williams C. Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 17721788. 2.Molendijk I et al. Intraluminal Injection of Mesenchymal Stromal Cells in Spheroids Attenuates Experimental Colitis. Journal of Crohn's and Colitis, 2016, 953964 3.Pak S eta al. Endoscopic Transplantation of Mesenchymal Stem Cell Sheets in Experimental Colitis in Rats. Scientific Reports | (2018) 8:11314 | DOI:10.1038/s41598-018-29617 4.CDC Facts and Figures 2015 5.Globaldata Pharmapoint 2018 6.Dahlhamer JM, MMWR Morb Mortal Wkly Rep. 2016;65(42):11661169. 7.Crohns and Colitis Foundation

About Remestemcel-L Mesoblasts lead product candidate, remestemcel-L, is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions. Remestemcel-L is thought to have immunomodulatory properties to counteract severe inflammatory processes by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

About Mesoblast Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. The Companys proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid-refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblasts licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking Statements This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as anticipate, believe, could, estimate, expect, goal, intend, likely, look forward to, may, plan, potential, predict, project, should, will, would and similar expressions and variations thereof. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. The risks, uncertainties and other factors that may impact our forward-looking statements include, but are not limited to: statements about the initiation, timing, progress and results of Mesoblast and its collaborators clinical studies; Mesoblast and its collaborators ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblasts product candidates, if approved; the potential benefits of strategic collaboration agreements and Mesoblasts ability to maintain established strategic collaborations; Mesoblasts ability to establish and maintain intellectual property on its product candidates and Mesoblasts ability to successfully defend these in cases of alleged infringement. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblasts actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. Unless required by law, we do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For further information, please contact:

Read more from the original source:
Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Inflamed Gut of Patients With Crohn's Disease and Ulcerative Colitis -...

Stem cells, repair cells, & growth factors: What is the latest? – The Times of India Blog

Stem cells, once seen as pluripotent cells that were going to cure all diseases, are having a recession. The science is revealing that, as is almost always the case, the story is more complicated than a super cell coming to the rescue. Here is an update.

Yes, stem cells exist. Yes, they are the origin of all the other cells in the body and, in a few cases (particularly in the eye), have successfully cured specific diseases.In most other cases, its the products of those cells that have been the best effectors of healing. At injury, when tissues have been torn or crushed, signaling factors are released from the cells within them.

Think of grapes at harvest, crushed into juice. The aroma of the crush, the fluid that is expressed, even the sound of the pressesall elicit a sensory response in the winemaker. This causes their lips to moisten, their noses to flare, and their mind to become excited at the anticipation of that years wine.

A similar thing happens within your body when an injury occurs (but without the pleasure). Here, the injury elicits a healing response. The signals that stimulate this response are produced primarily from proteins called cytokines, which are released from broken blood vessels at the site of injury. Other stimulants include fluid that was once inside the cells of the tissuesbut is now in the extracellular space, causing swelling and bruisingand messages sent by nerve fibers that, when injured, signal the brain to start an additional cascade of healing responses.

A major part of this healing response is directed by self-repair cellsthink of them as the sons and daughters ofstem cells. They rush to the site of injury, directing the next stages of healing. A subset of cells called M1 macrophages removes dead tissue, while M2 macrophages suppress inflammation and help the remaining healthy cells lay down new collagen during the rebuilding process.

What this means for the clinician caring for an injured patient is that there are many ways to interact with, and even accelerate, the healing response. The most potent tools we have are growth factors from either the patients own blood components (called platelets) or from birth tissues and amniotic fluid that surround a growing fetus. These birth products are donated at the time of C-section from healthy mothers then provided by tissue banks for use in the clinic.

Our research, and that of others, has shown that these factors can directly affect the chemistry of injured tissues or arthritic joints and generate a much more robust call for self-repair cells. Simply put, we caninsertthe signaling factors that direct healing more effectively than we canharvestcells. And since the human body has billions of stem cells, self-repair cells, and other injury response systems, it makes more sense toinject factors that recruit and stimulate these healing cellsthan to try to inject stem cells harvested from fat or bone.

Todays injections are mixtures of the strongest growth factors and cytokines. Our goal is to shorten the healing time of any injury. We then let the patients body make the wine.

DISCLAIMER : Views expressed above are the author's own.

Read more:
Stem cells, repair cells, & growth factors: What is the latest? - The Times of India Blog